Halozyme Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning our product candidates in development, potential benefits and attributes of rHuPH20 and our product candidates including safety and clinical profile, anticipated clinical and regulatory events and our intended actions, that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are usually (but not always) identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of risks and uncertainties including clinical trial enrollment and results, regulatory approval requirements, unexpected expenditures and costs, unexpected results or delays in development and regulatory review, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2013. Halozyme does not undertake to
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved